Indeed, gene expression profiling studies and screens employing small molecule kinase inhibitors or small interfering RNA (siRNA) libraries have demonstrated that PLK1 inhibition may lead to the elimination of CSCs in a range of tumours, including neuroblastoma19, glioblastoma20, as well as breast cancer21, 22. This evidence concerns the gene PLK1 and neoplasm.